




# A Clinical Trial to Compare the Efficacy of Tadalafil in Pulmonary Hypertension and Interstitial Lung Disease

Guitti Pourdowlat<sup>1</sup>, Bahador Bagheri <sup>2,3</sup>, Habib Emami<sup>1</sup>, Seyyed Reza Seyyedi<sup>1</sup>, Mahboubeh Darban<sup>4,\*</sup>

<sup>1</sup> Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>2</sup> Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran

<sup>3</sup> Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland

<sup>4</sup> Department of Internal Medicine, Kowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran

\*Corresponding Author: Department of Internal Medicine, Kowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran. Email: dr.mdarban@gmail.com

Received: 21 July, 2024; Revised: 23 April, 2025; Accepted: 19 May, 2025

## Abstract

**Background:** To determine the effects of oral tadalafil on respiratory function in patients with interstitial lung disease (ILD), both with and without pulmonary hypertension (PH).

**Methods:** Patients with ILD-PH (WHO classes 2 and 3) were assigned to group A, while patients with ILD without PH were assigned to group B. Participants in both groups received a daily dose of 40 mg oral tadalafil as an add-on therapy to their conventional treatments for a duration of 6 months. The study outcomes included changes in forced vital capacity (FVC), total lung capacity (TLC), diffusion lung capacity for carbon monoxide (DLCO), residual volume (RV), and a 6-minute walk distance (6MWD).

**Results:** Of the 38 patients enrolled, 34 completed the 6-month treatment and were included in the final analysis. The mean age of participants was 50 years. At 6 months, no significant changes were observed in FVC, forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and DLCO. However, patients receiving tadalafil showed a significant improvement in median (interquartile range [IQR]) TLC after 6 months of treatment (77.1 [70.2-80.1] mL in group A versus 86.2 [86.3 - 93.1] mL in group B,  $P = 0.002$ ) and in median (IQR) RV (83.1 [79.1 - 85.2] mL in group A versus 90.2 [86.3 - 93.1] mL in group B,  $P = 0.02$ ). Additionally, no significant differences were noted in pulmonary arterial pressure (PAP) and 6MWD. No serious adverse effects were reported.

**Conclusions:** A 6-month therapy with tadalafil was shown to partially improve respiratory function in patients with ILD, both with and without PH. This treatment demonstrated an acceptable safety profile.

**Keywords:** Tadalafil, Pulmonary Hypertension, Interstitial Lung Disease, Systemic Sclerosis

## 1. Background

Systemic sclerosis (SSc) is a heterogeneous autoimmune disease affecting connective tissues. Vasculopathy, inflammation, excessive collagen formation, and fibrosis are significant complications observed in SSc (1, 2). Interstitial lung disease (ILD) and pulmonary hypertension (PH) are critical complications of SSc and remain major causes of morbidity and mortality. The pathogenesis of ILD is not well-clarified. Due to vascular injury, consequent inflammation, and

immunologic response, a large number of fibroblasts are produced. Fibroblasts, along with other factors including pro-inflammatory cytokines and transforming growth factors, are responsible for fibrosis (3, 4).

Pulmonary hypertension, another complication of SSc, is defined by a mean pulmonary arterial pressure (PAP) of  $> 25$  mmHg with a pulmonary capillary wedge pressure (PCWP)  $< 15$  mmHg on right heart catheterization (RHC). According to the World Health Organization (WHO) classification, there are five groups

for PH based on etiology. Group 1 PH is frequently seen in patients with SSc (5, 6). Given the lack of specific signs and symptoms of PH, it is recommended that all patients with SSc be evaluated for PH. Phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil and tadalafil, calcium channel blockers, endothelin receptor antagonists, and prostacyclin analogs are widely used for PH management (7). Among these, PDE-5 inhibitors, which are well-known drugs for erectile dysfunction, are often considered beneficial agents for PH. Importantly, they typically lack serious safety concerns (8, 9). Phosphodiesterase-5 inhibitors are associated with notable vasodilatory effects in PAP. Additionally, some studies have provided evidence for their anti-inflammatory and anti-fibrotic properties (10).

## 2. Objectives

In contrast to PH, the efficacy of tadalafil in ILD remains unknown, and current data are not conclusive. This was the purpose of our study. The present trial was designed to compare the efficacy of oral tadalafil in ILD patients with and without PH.

## 3. Methods

### 3.1. Study Design

This parallel-group, non-randomized, single-center clinical trial was conducted at Masih-Daneshvari Hospital, Tehran, Iran. Thirty-four patients aged 18 to 75 years with a diagnosis of SSc, according to the American College of Rheumatology classification criteria, were included (11). Pulmonary hypertension was diagnosed using echocardiography. CT imaging of the chest and common pulmonary function tests, including body box test, diffusing capacity for carbon monoxide (DLCO), total lung capacity (TLC), and spirometry, were used for ILD diagnosis. Patients with ILD-PH (WHO classes 2 and 3) were assigned to group A, and subjects with ILD were assigned to group B. Study subjects in both groups were initially administered 20 mg of oral tadalafil (Adcirca®, Lilly, USA) once daily for 2 weeks. After an initial evaluation of safety, the dose was titrated to 40 mg/day. The duration of treatment was 6 months. The study was approved by the local Ethics Committee, and written consent was obtained from patients prior to participation. The clinical trial registry number was [IRCT20190202042598N1](#). Patients were excluded if they

had a history of nitrates and endothelin antagonists use, chronic obstructive pulmonary disease, idiopathic PH, history of PDE-5 inhibitors use, diabetes mellitus, essential hypertension, coronary artery disease, renal failure, malignancies, history of hypersensitivity to drugs, or any autoimmune diseases associated with SSc. Patients were discontinued from the study for the following reasons: Safety concerns, loss to follow-up, or voluntary discontinuation.

### 3.2. Assessment of Response


Spirometry, the 6-minute walk test (6MWT), DLCO, TLC, and echocardiography were used for response assessment at month 6. The collected parameters were compared with baseline values. Spirometry was performed using the Spirolab III® (MIR, Italy) according to standard guidelines. Diffusion lung capacity for carbon monoxide was measured using the Pulmo Lab 501 (Morgan Medical, USA) by the single-breath method, following European Respiratory Society guidelines. The TLC was measured using a body box. For the 6-minute walk test (6MWT), the 6-minute walk distance (6MWD) was recorded at baseline and at 6 months. Changes in forced vital capacity (FVC) over 6 months were the primary endpoints. Changes in DLCO and the number of adverse effects of the treatment were the secondary endpoints of the trial.

### 3.3. Assessment of Safety

Patients were evaluated monthly for myalgia, hypotension, visual defects, and hearing loss. Additionally, renal and hepatic functions were monitored monthly. Included patients were instructed to contact the study staff in the event of any possible side effects. Drugs with potential effects on hepatic cytochromes, including itraconazole, ketoconazole, clarithromycin, erythromycin, chloramphenicol, and antivirals such as lopinavir, were contraindicated for study subjects.

### 3.4. Statistical Analysis

Continuous variables were expressed as mean (SD) or median and interquartile range (IQR). A significance level (P-value) of less than 0.05 was considered significant. The total number of 45 patients was calculated for randomization based on the assumption of a 20% dropout rate among study patients, with an 80%



**Figure 1.** Consort diagram detailing study subjects

power and an anticipated effect size of 0.1. To test differences and proportions between the two groups, the chi-square ( $\chi^2$ ) test and Fisher's exact test were used. The Shapiro-Wilk test was used to check the normal distribution of data. The Wilcoxon signed-rank test was used for comparing means. Subgroup analysis was performed using Mantel-Haenszel (MH) chi-square tests. SPSS software version 21.0 (Chicago, USA) was used for data analysis.

## 4. Results

### 4.1. Baseline Characteristics

Of the 38 patients, 4 did not complete the study (1 met the exclusion criteria, and 3 did not use the drugs). [Figure 1](#) shows the flow diagram of included patients. Clinical characteristics of the 34 study subjects are shown in [Table 1](#). The mean age was  $49.7 \pm 11.1$  years in group A and  $48.9 \pm 9.9$  years in group B. Females comprised 76% of the study patients. At baseline, FVC was  $67.3 \pm 14.2\%$  of the predicted value in group A and

$77.2 \pm 16.7\%$  of the predicted value in group B. No significant differences were noted in baseline characteristics. All patients were asked to discontinue similar medications 2 months before the initiation of the trial. The mean number of days since the last treatment was 61 days in group A and 63 days in group B.

### 4.2. Efficacy Measures

As presented in [Table 2](#), the baseline median (IQR) FVC was 67.2 (59.4 - 78.8) % of the predicted value in group A and 68.4 (60.2 - 78.3) % of the predicted value in group B. All study patients completed the treatments. Compared to baseline, tadalafil therapy had no significant effect on FVC over the course of 6 months ( $P > 0.05$ ). As shown in [Table 2](#), spirometry parameters showed no significant improvement after 6 months of follow-up in both study groups. Additionally, there were no significant differences between groups in forced expiratory volume in 1 second (FEV1) and FEV1/FVC values ( $P > 0.05$ ). After 6 months, no significant difference was noted in DLCO between study groups. There was a slight

**Table 1.** Characteristics of Participants at Baseline <sup>a</sup>

Characteristics	ILD-PH (n = 18)	ILD (n = 16)	P-Value
Age (y)	49.7 ± 11.1	48.9 ± 9.9	0.3
Age (range)	39 - 70	41 - 75	0.2
Female	11 (78)	12 (75)	0.2
Male	7 (22)	4 (25)	0.8
LV ejection fraction (%)	59.8 ± 6.1	60.7 ± 7.5	0.6
Hemoglobin (g/L)	100 ± 8.6	99 ± 8.8	0.2
Total WBC count (10 <sup>9</sup> /L)	7.8 ± 5.24	7.5 ± 3.1	0.5
<b>Medical history</b>			
Sedatives	3 (16)	2 (12)	0.3
Anti-depressants	2 (11)	2 (12)	0.2
Oral contraceptives	5 (26)	4 (25)	0.6
Supplements	8 (44.4)	6 (37)	0.7
Pirfenidone	9 (50)	11 (68.7)	0.5
Aerosols	10 (55.5)	10 (62.5)	0.2
Pantoprazole	11 (61)	12 (75)	0.7
Prednisolone	8 (44.4)	10 (62.5)	0.2

Abbreviations: ILD, interstitial lung disease; PH, pulmonary hypertension.

<sup>a</sup> Values are expressed as mean ± SD or No. (%) unless otherwise indicated.

increase in median (IQR) DLCO in group A [(from 69.3 (54.2 - 81.3) to 70.31 (66.2 - 77.3), and a slight decline in group B [from 68.4 (60.2 - 78.3) to 67.1 (65.2 - 81.3)] after 6 months of follow-up.

A significant difference was noted in median (IQR) TLC after 6 months of treatment [77.1 (70.2 - 80.1) mL in group A versus 86.2 (86.3 - 93.1) mL in group B,  $P = 0.002$ ]. Moreover, there was a significant difference in median (IQR) RV between the two study groups after 6 months [83.1 (79.1 - 85.2) mL in group A versus 90.2 (86.3 - 93.1) mL in group B,  $P = 0.02$ ]. No significant differences were observed in pulmonary arterial pressure (PAP) at baseline and at 6 months. Finally, as shown in Table 2, no significant differences were observed in the 6MWD between group A and group B.

Additionally, analysis of data stratified by age and sex indicated that the rate of response failed to reach a significant difference in patients aged > 40 years ( $P = 0.8$ ) in either group A or group B. Similarly, there was no significant difference in the rate of response between females and males in both study groups ( $P = 0.4$ ).

#### 4.3. Safety Measures

In group A, 3 patients (16%) exhibited mild respiratory symptoms (sneezing and sore throat), and 4 patients

(22%) experienced mild gastrointestinal (GI) upset (nausea and vomiting). In group B, 3 patients (19%) had mild GI upset, 2 patients (12%) experienced transient visual disturbances, and 1 patient (6%) developed mild tinnitus. Moreover, there was no significant difference in the rate of side effects among patients aged > 40 years ( $P = 0.09$ ). No patient died, and no patient was withdrawn due to untoward effects of the treatments.

#### 5. Discussion

This study primarily focused on assessing alterations in respiratory and structural features following the administration of tadalafil in patients with ILD-PH and ILD. It is worth mentioning that the clinical paradigm of ILD among SSc patients could garner increased attention. Although tadalafil may exhibit considerable effects targeting PH in ILD patients, the therapeutic outcomes related to ILD and the pathophysiology of pulmonary fibrosis remain unclear. In summary, our results indicated no significant differences between study groups regarding their baseline demographic and respiratory characteristics. A multivariable overview also noted that our study subjects were homogeneous based on age, sex, and past medication history. The 6-month follow-up revealed no significant changes in FVC, FEV1, FEV1/FVC, DLCO, and 6MWT. However, TLC and RV

**Table 2.** Changes in Outcomes Before and After 6 Months of Treatment with Tadalafil <sup>a</sup>

Characteristics	Group A; ILD - PH (N = 18)	Group B; ILD (N = 16)	P (Within Group)	P (Between Group)
<b>DLCO (%)</b>			> 0.5	> 0.5
Before	69.3 (54.2 - 81.3)	68.4 (60.2 - 78.3)		
After	70.31 (66.2 - 77.3)	67.1 (65.2 - 81.3)		
<b>FEV1 (%)</b>			> 0.5	> 0.5
Before	77.2 (69.2 - 79.8)	78.8 (70.2 - 80.8)		
After	78.2 (65.2 - 79.8)	79.2 (69.2 - 81.2)		
<b>FVC (%)</b>			> 0.5	> 0.5
Before	67.2 (59.4 - 78.8)	66.7 (59.4 - 71.3)		
After	68.9 (60.4 - 77.8)	66.9 (59.1 - 72.8)		
<b>FEV1/FVC</b>			> 0.5	> 0.5
Before	(85.4 - 92.9)	91.9 (84.7 - 93.9)		
After	89.8 (88.4 - 91.9)	89.1 (85.4 - 91.9)		
<b>TLC (mL)</b>			> 0.5	0.002
Before	76.3 (69.4 - 78.8)	77.1 (75.2 - 80.5)		
After	77.1 (70.2 - 80.1)	86.2 (86.3 - 93.1)		
<b>RV (mL)</b>			> 0.5	0.02
Before	80.2 (55.2 - 82.8)	77.1 (75.2 - 80.5)		
After	83.1 (79.1 - 85.2)	90.2 (86.3 - 93.1)		
<b>6MWD (m)</b>			> 0.5	> 0.5
Before	288.2 (276 - 312)	279.4 (276 - 319)		
After	299.1 (272 - 319)	301.1 (288 - 311)		
<b>O<sub>2</sub>Sat (%)</b>			> 0.5	> 0.5
Before	80.1 (77.5 - 84.4)	81.2 (80.1 - 85.4)		
After	84.2 (79.2 - 86.2)	85.2 (77.2 - 86.2)		
<b>PAP (mm/Hg)</b>			> 0.5	> 0.5
Before	36.4 (31 - 43)	36.4 (31 - 39)		
After	36.9 (32 - 39)	37.9 (33 - 36)		

Abbreviations: ILD, interstitial lung disease; PH, pulmonary hypertension; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusion lung capacity for carbon monoxide; RV, residual volume; 6MWD, 6-minute walk distance; PAP, pulmonary artery pressure.

<sup>a</sup> Values are expressed as median (IQR).

were significantly improved after treatment in SSC patients with ILD compared to those with PH.

Tadalafil is a member of the phosphodiesterase 5 inhibitor family, known for its efficacy against PH due to its vasodilatory effects. The efficacy, healing rate, and safety of tadalafil targeting either primary or secondary PH have been well discussed (5). Considering the baseline characteristics of the participants, although this study indicated no significant differences in age and sex between patients with PH and those with isolated ILD, Mathai et al. suggested that the responsiveness of PH to tadalafil relies on age, sex, primary functional capacities, and PH etiology. Future research should clarify the possible presence of dependency factors underlying this issue (12).

The initial application of tadalafil revealed that not only did TLC and RV undergo considerable enhancement in patients with pulmonary fibrosis, but its safety and tolerance were also well-established (5, 6). Zimmermann et al. suggested that while the administration of tadalafil in patients with PH secondary to ILD could not enhance 6MWD, the hemodynamic and arterial wedge pressure status could reach a more optimistic state (13). Interestingly, Parida et al. observed that six months of tadalafil treatment, despite FVC, 6MWT, and DLCO, could elevate TLC levels in SSC patients with ILD and pulmonary fibrosis compared to the placebo-treated group (14).

In contrast, Hassoun et al. included SSC patients with associated PH and designed a 36-week prospective combination therapy using tadalafil and ambrisentan.

This combined therapy improved cardiac and hemodynamic values, including RV structure and function, pro-BNP, and arterial resistance in SSc patients with PH. This could be possibly related to the absence of analytic judgment according to combination therapy and monotherapy in our study (15). Furthermore, Coghlan et al. investigated the efficacy of tadalafil and ambrisentan combination therapy versus current monotherapies. They included SSc patients with associated PH and found that combination therapy could cause a higher rate of efficacy with a similar rate of adverse effects (16).

Even though the enrolled elements of hemodynamic and cardiac status of PH phenomena could be altered by the administration of tadalafil, the efficacy of this agent in ILD and pulmonary dysfunction needs further elucidation (17). Besides, Galie et al.'s study showed that tadalafil 40 mg was well tolerated and could improve exercise capacity and reduce the worsening of PH (18). Chauvelot et al.'s study showed that PH treatment was not associated with a better outcome in patients with SSc-PH-ILD compared to patients with SSc-PH (19).

Subjects with SSc-ILD usually have increased production of interleukin (IL)-8 and tumor necrosis factor-alpha (TNF- $\alpha$ ) in bronchoalveolar lavage (BAL) samples (20). Moreover, there is an augmented expression of Toll-like receptor (TLR) 4 in lung fibroblasts of patients with SSc-ILD (21). Toll-like receptor 4 is widely recognized as a part of innate immunity but can be activated by other circumstances like coronary artery procedures and ILD (22, 23). Interestingly, IL-33 has been shown to be involved in the pathogenesis of SSc (24). Additionally, it has been previously shown that sildenafil, as a PDE5 inhibitor, could prevent cardiac fibrosis possibly through alteration in transforming growth factor-beta 1 (TGF- $\beta$ 1) production (25). A study by Higuchi et al. indicated that sildenafil could subside SSc skin fibroblasts induced by TGF- $\beta$ 1 (26).

together, there are a limited number of medical therapies for ILD induced by SSc. Immunosuppressive medications and drugs against PH are all available options in addition to anti-fibrotic agents.

### 5.1. Study Limitation

The present study has several limitations that should be acknowledged. Due to the limited number of patients, our findings should be confirmed in larger,

randomized studies with sufficient power. The untoward effects of long-term treatment with sildenafil should be assessed by further studies.

### 5.2. Conclusions

We demonstrated that a 6-month therapy with tadalafil was effective in partially improving respiratory functions in patients with ILD, both with and without PH. This treatment exhibited an acceptable safety profile.

### Acknowledgements

The authors wish to thank the staff of Masih Daneshvari Hospital for their assistance with this project.

### Footnotes

**Authors' Contribution:** G. P. and M. D. designed the study. B. B. drafted the manuscript and analyzed collected data. M. D. and R. S. collected data. H. E. and G. P. revised the manuscript.

**Clinical Trial Registration Code:** IRCT20190202042598N1.

**Conflict of Interests Statement:** The authors declared no conflict of interests.

**Data Availability:** The data presented in this study are uploaded during submission as a supplementary file and are openly available for readers upon request.

**Ethical Approval:** IR.SBMU.NRITLD.REC.1396.414

**Funding/Support:** This study was supported by Vice Chancellor of Research and Technology of Shahid Beheshti University of Medical Sciences.

**Informed Consent:** Written consent was obtained from patients prior to participation.

### References

1. Denton CP, Khanna D. Systemic sclerosis. *Lancet*. 2017;**390**(10103):1685-99. [PubMed ID: 28413064]. [https://doi.org/10.1016/S0140-6736\(17\)30933-9](https://doi.org/10.1016/S0140-6736(17)30933-9).
2. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. *Lancet*. 2022;**400**(10354):769-86. [PubMed ID: 35964592]. [https://doi.org/10.1016/S0140-6736\(22\)01052-2](https://doi.org/10.1016/S0140-6736(22)01052-2).



3. Shah Gupta R, Koteci A, Morgan A, George PM, Quint JK. Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review. *BMJ Open Respir Res.* 2023;**10**(1). [PubMed ID: 37308252]. [PubMed Central ID: PMC10277538]. <https://doi.org/10.1136/bmjresp-2022-001291>.
4. Denton CP, De Lorenzis E, Roblin E, Goldman N, Alcaccer-Pitarch B, Blamont E, et al. Management of systemic sclerosis: British Society for Rheumatology guideline scope. *Rheumatol Adv Pract.* 2023;**7**(1):rkad022. [PubMed ID: 36923262]. [PubMed Central ID: PMC10010890]. <https://doi.org/10.1093/rap/rkad022>.
5. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. *JAMA.* 2022;**327**(14):1379-91. [PubMed ID: 35412560]. <https://doi.org/10.1001/jama.2022.4402>.
6. Olsson KM, Corte TJ, Kamp JC, Montani D, Nathan SD, Neubert L, et al. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management. *Lancet Respir Med.* 2023;**11**(9):820-35. [PubMed ID: 37591300]. [https://doi.org/10.1016/S2213-2600\(23\)00259-X](https://doi.org/10.1016/S2213-2600(23)00259-X).
7. Mandras SA, Mehta HS, Vaidya A. Pulmonary Hypertension: A Brief Guide for Clinicians. *Mayo Clin Proc.* 2020;**95**(9):1978-88. [PubMed ID: 32861339]. <https://doi.org/10.1016/j.mayocp.2020.04.039>.
8. Grunig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, et al. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. *J Am Coll Cardiol.* 2024;**83**(4):473-84. [PubMed ID: 38267108]. <https://doi.org/10.1016/j.jacc.2023.10.045>.
9. Dawes TJW, McCabe C, Dimopoulos K, Stewart I, Bax S, Harries C, et al. Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. *Respirology.* 2023;**28**(3):262-72. [PubMed ID: 36172951]. <https://doi.org/10.1111/resp.14378>.
10. Smukowska-Gorynia A, Gosciniak W, Wozniak P, Iwanczyk S, Jaxa-Kwiatkowska K, Slawek-Szmyt S, et al. Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases. *Pharmaceuticals (Basel).* 2023;**16**(9). [PubMed ID: 37765060]. [PubMed Central ID: PMC10534675]. <https://doi.org/10.3390/ph16091252>.
11. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. *Ann Rheum Dis.* 2013;**72**(11):1747-55. [PubMed ID: 24092682]. <https://doi.org/10.1136/annrheumdis-2013-204424>.
12. Mathai SC, Hassoun PM, Puhon MA, Zhou Y, Wise RA. Sex differences in response to tadalafil in pulmonary arterial hypertension. *Chest.* 2015;**147**(1):188-97. [PubMed ID: 25122150]. [PubMed Central ID: PMC4285077]. <https://doi.org/10.1378/chest.14-0263>.
13. Zimmermann GS, von Wulffen W, Huppmann P, Meis T, Ihle F, Geiseler J, et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. *Respirology.* 2014;**19**(5):700-6. [PubMed ID: 24697923]. <https://doi.org/10.1111/resp.12294>.
14. Parida J, Nath A, Neyaz Z, Agarwal V. A Double Blind Randomized Control Trial of Oral Tadalafil in Interstitial Lung Disease of Scleroderma. 1679. *Arth Rheumatol.* 2014;**66**: S739.
15. Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, et al. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med.* 2015;**192**(9):1102-10. [PubMed ID: 26360334]. [PubMed Central ID: PMC4642204]. <https://doi.org/10.1164/rccm.201507-1398OC>.
16. Coghlan JG, Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. *Ann Rheum Dis.* 2017;**76**(7):1219-27. [PubMed ID: 28039187]. [PubMed Central ID: PMC5530350]. <https://doi.org/10.1136/annrheumdis-2016-210236>.
17. Sato T, Ambale-Venkatesh B, Lima JAC, Zimmerman SL, Tedford RJ, Fujii T, et al. The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. *Pulm Circ.* 2018;**8**(1):2045893217748310. [PubMed ID: 29251556]. [PubMed Central ID: PMC6018906]. <https://doi.org/10.1177/2045893217748307>.
18. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. *Circulation.* 2009;**119**(22):2894-903. [PubMed ID: 19470885]. <https://doi.org/10.1161/CIRCULATIONAHA.108.839274>.
19. Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, et al. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. *Arthritis Rheumatol.* 2021;**73**(2):295-304. [PubMed ID: 32892515]. <https://doi.org/10.1002/art.41512>.
20. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. *Am J Respir Crit Care Med.* 2008;**177**(1):1248-54. [PubMed ID: 18369202]. <https://doi.org/10.1164/rccm.200706-877OC>.
21. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, et al. Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. *Am J Pathol.* 2013;**182**(1):192-205. [PubMed ID: 23141927]. [PubMed Central ID: PMC3538029]. <https://doi.org/10.1016/j.ajpath.2012.09.007>.
22. Bagheri B, Sohrabi B, Movassaghpur A, Mashayekhi S, Garjani A, Shokri M, et al. Monocyte expression of toll-like receptor-4 in patients with stable angina undergoing percutaneous coronary intervention. *Iran J Immunol.* 2012;**9**(3):149-58.
23. Kang H. Role of MicroRNAs in TGF-beta Signaling Pathway-Mediated Pulmonary Fibrosis. *Int J Mol Sci.* 2017;**18**(12). [PubMed ID: 29186838]. [PubMed Central ID: PMC5751130]. <https://doi.org/10.3390/ijms18122527>.
24. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. *Clin Rheumatol.* 2011;**30**(6):825-30. [PubMed ID: 21246230]. <https://doi.org/10.1007/s10067-011-1686-5>.
25. Gong W, Yan M, Chen J, Chaugai S, Chen C, Wang D. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor beta-induced Smad signaling. *Front Med.* 2014;**8**(4):445-55. [PubMed ID: 25416030]. <https://doi.org/10.1007/s11684-014-0378-3>.
26. Higuchi T, Kawaguchi Y, Takagi K, Tochimoto A, Ota Y, Katsumata Y, et al. Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in

patients with systemic sclerosis. *Clin Immunol.* 2015;**161**(2):333-8.  
[PubMed ID: 26387628]. <https://doi.org/10.1016/j.clim.2015.09.010>.